November 5, 2026

Santen Announces Share Buyback

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; President and CEO: Takeshi Ito; hereinafter, Santen) announced that its Board of Directors resolved today to repurchase its own shares in accordance with Article 156 of the Companies Act (Japan), as applied pursuant to Article 165, paragraph 3.

1. Reasons for Repurchase of Own Shares

Santen considers returning profits to shareholders as one of its top management priorities. Taking into consideration its business environments and financial conditions, Santen decided to implement a share buyback to enhance shareholder returns, further improve capital efficiency and pursue a flexible capital policy.

2. Details of Repurchase

(1) Class of shares to be repurchased	Common shares
(2) Total number of shares to be repurchased	16,000,000 shares (maximum) *Representing 5.0% of the total number of shares outstanding (excluding treasury shares)
(3) Total amount of repurchase	35.0 billion yen (maximum)
(4) Period of repurchase	November 6, 2026 to May 10, 2027
(5) Method of repurchase	Open-market repurchase by discretionary trading method

Santen plans to cancel the repurchased shares by its Board of Directors resolution in accordance with Article 178 of the Companies Act (Japan).

There is a possibility that some of the purchases may not be made depending on market conditions and other factors.

(Reference) Treasury Shares Information as of October 31, 2026

Total number of shares outstanding (excluding treasury shares)	321,808,563 shares
Treasury shares	505,591 shares

Contact:
Guillaume Sakuma
Global Head of Investor Relations
E-mail: ir@santen.com

About Santen

Santen is a global pharmaceutical company committed to advancing eye health and improving lives through better vision. Founded in 1890 in Osaka, Japan, Santen makes use of more than 135 years of experience in research and development, manufacturing, and marketing of pharmaceuticals and medical devices to help people around the globe maintain and improve their eye health. Santen focuses exclusively on eye health and its portfolio includes glaucoma, dry eye, infection, allergy, age-related macular degeneration, and myopia. Santen's products and services are available in more than 60 countries and regions. Guided by its Core Principle "*Tenki ni sanyo suru*" – Exploring the secrets and mechanisms of nature in order to contribute to people's health – Santen combines its expertise with deep patient focus to contribute to the realization of "Happiness with Vision."
For more information, please visit https://www.santen.com/en.